P2RY1 and Stroke: In the PLATO and TRITON‐TIMI 38 trials, on the background of dual antiplatelet treatment, stronger inhibitors of ADP than clopidogrel were associated with lower nonfatal MI, stroke, or CVD deaths.10, 11 Some earlier studies suggest that ADP blockade may be equal or superior to aspirin, with lower adverse effects,35, 36 and this could indicate that ADP receptor inhibition should be considered in regimens of prolonged monotherapy after initial dual antiplatelet therapy.